Cavazzoni urges proactive measures to avoid CRLs for biologics manufacturing issues
Regulatory NewsFerdous Al-FaruqueBiologics License Application (BLA)Biologics/ biosimilars/ vaccinesManufacturingRegulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)